Loading data for TRAW — first visit, this takes a few seconds.
Traws Pharma, Inc.
0.53 +0.01 (1.92%)
0.53 +0.00%
- Capitalización de mercado
- $8.19M
- Volumen
- 33.6K
- Próxima fecha de resultados
- Aug 14, 2025
Traws Pharma, Inc. (TRAW): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | -100.00% |
| EPS | -$0.18 | +$0.27 | +97.96% |
Métricas
- Precio de compra
- 0.36
- Beneficio neto (TTM)
- -16.4M
- 1.60
- -1.83
- n/a
- -0.28
- P/B (TTM)
- 4.80
- P/S (TTM)
- n/a
- Fecha de resultados
- Aug 14, 2025
- Precio de venta
- 0.68
- Volumen
- 33,561
- Volumen medio (20D)
- 141,218
- Abierto
- 0.52
- Anterior Cerrar
- 0.52
- Rango del día
- 0.52 - 0.55
- Rango de 52 semanas
- 0.43 - 3.27
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Traws Pharma, Inc.
Ver perfil →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Industria Biotechnology
Sector Healthcare
IPO Fecha Jul 25, 2013
Empleados 4
Bolsa de Valores NasdaqCM
Símbolo bursátil TRAW
Sitio web https://www.trawspharma.com